Completed PHASE3 INTERVENTIONAL 2-arm NCT05387070

PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

PaTHway CHINA TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism

Sponsor: Visen Pharmaceuticals (Shanghai) Co., Ltd.

Conditions Endocrine System Diseases Hypoparathyroidism Parathyroid Diseases Parathyroid Hormone Deficiency

Interventions TransCon PTH placebo

Updated 4 times since 2022 Last updated: Jan 14, 2026 Started: Jul 28, 2021 Primary completion: Jan 4, 2023 Completion: Jan 8, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Endocrine System Diseases and Hypoparathyroidism and is currently completed. Visen Pharmaceuticals (Shanghai) Co., Ltd. leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE3

Status: Recruiting → Completed
Sep 2024 — Feb 2026 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jun 2022 — Jul 2024 [monthly]

Recruiting PHASE3

First recorded

Jul 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Visen Pharmaceuticals (Shanghai) Co., Ltd.

Data source: Visen Pharmaceuticals (Shanghai) Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China